Introduction Little is known about the clinical characteristics of women at increased risk for
abnormal uterine bleeding (UB) during anticoagulation for venous thromboembolism (VTE) …

Background Women presenting with uterine bleeding during the course of anticoagulant
therapy for venous thromboembolism (VTE) present a difficult therapeutic dilemma due to …

Women receiving vitamin K antagonists (VKAs) require adequate contraception because of
the potential for fetal complications. It is unknown whether the use of hormonal therapy …

Abnormal uterine bleeding is highly incident among women of reproductive age treated with
anticoagulants for venous thromboembolism (VTE), resulting in decreased quality of life …

Direct oral anticoagulants (DOACs) apixaban and rivaroxaban have been endorsed by
clinical practice guidelines for the outpatient treatment of venous thromboembolism (VTE) …

Preliminary data and clinical experience have suggested an increased risk of abnormal
uterine bleeding (AUB) in women of reproductive age treated with anticoagulants, but solid …

Objective To investigate the characteristics and outcome of abnormal vaginal bleeding in
women receiving edoxaban or warfarin for treatment of venous thromboembolism (VTE) …

Study Objectives Direct oral anticoagulants (DOACs), such as apixaban and rivaroxaban
have been endorsed by clinical practice guidelines for the outpatient treatment of venous …

Introduction Rivaroxaban is a convenient oral anticoagulant for patients with venous
thromboembolism (VTE). The impact of rivaroxaban and vitamin K antagonists (VKAs) on …

Abnormal vaginal bleeding can complicate direct oral anticoagulant (DOAC) treatment. We
aimed to investigate the characteristics of abnormal vaginal bleeding in patients with venous …